These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 2721109

  • 1. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG, Kirsten EB, Brewington J.
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [Abstract] [Full Text] [Related]

  • 2. Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study.
    Singh BN, Kaplinsky E, Kirsten E, Guerrero J.
    Am Heart J; 1988 Dec; 116(6 Pt 1):1542-51. PubMed ID: 3057844
    [Abstract] [Full Text] [Related]

  • 3. Metabolite cumulation during chronic propafenone dosing in arrhythmia.
    Kates RE, Yee YG, Winkle RA.
    Clin Pharmacol Ther; 1985 Jun; 37(6):610-4. PubMed ID: 4006362
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography.
    Shirayama Y, Doki K, Sekiguchi Y, Aonuma K, Kohda Y, Homma M.
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28929504
    [Abstract] [Full Text] [Related]

  • 5. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
    Geibel A, Zehender M, Hohnloser S, Landsrath C, Meinertz T, Just H.
    Z Kardiol; 1988 Jul; 77(7):464-9. PubMed ID: 2463720
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW, Vozeh S, Ha HR, Follath F.
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [Abstract] [Full Text] [Related]

  • 7. Effect of propafenone in patients with stable ventricular arrhythmias.
    de Soyza N, Terry L, Murphy ML, Thompson CH, Doherty JE, Sakhaii M, Dinh H.
    Am Heart J; 1984 Aug; 108(2):285-9. PubMed ID: 6380253
    [Abstract] [Full Text] [Related]

  • 8. ECG changes and plasma concentrations of propafenone and its metabolites in a case of severe poisoning.
    Fonck K, Haenebalcke C, Hemeryck A, Belpaire F, Jordaens L, Calle P, Buylaert W.
    J Toxicol Clin Toxicol; 1998 Aug; 36(3):247-51. PubMed ID: 9656983
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of oral propafenone in chronic ventricular arrhythmias: a placebo controlled cross-over exercise study.
    Härtel G.
    Eur Heart J; 1985 Feb; 6(2):123-9. PubMed ID: 3891347
    [Abstract] [Full Text] [Related]

  • 10. Propafenone for the treatment of refractory complex ventricular ectopic activity.
    Hammill SC, Sorenson PB, Wood DL, Sugrue DD, Osborn MJ, Gersh BJ, Holmes DR.
    Mayo Clin Proc; 1986 Feb; 61(2):98-103. PubMed ID: 3945115
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode.
    Patel H, Ghoghari A, Bhatt C, Shah S, Jha A, Desai N, Srinivas NR.
    Biomed Chromatogr; 2017 Oct; 31(10):. PubMed ID: 28261841
    [Abstract] [Full Text] [Related]

  • 14. Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity.
    Hodges M, Salerno D, Granrud G.
    Am J Cardiol; 1984 Nov 14; 54(9):45D-50D. PubMed ID: 6388303
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers.
    Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S.
    J Pharmacol Exp Ther; 1997 Oct 14; 283(1):39-45. PubMed ID: 9336306
    [Abstract] [Full Text] [Related]

  • 17. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy.
    Steurer G, Weber H, Schmidinger H, Plass H, Frey B, Pürerfellner H, Probst P.
    Eur Heart J; 1991 Apr 14; 12(4):526-32. PubMed ID: 2065687
    [Abstract] [Full Text] [Related]

  • 18. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE, Vozeh S, Ha HR, Taeschner W, Follath F.
    Am J Cardiol; 1991 May 01; 67(11):1022-6. PubMed ID: 2018005
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A, Boriani G, Marchesini B, Strocchi E, Tomasi L, Balducelli M, Frabetti L, Ambrosioni E, Magnani B.
    Cardiovasc Drugs Ther; 1990 Feb 01; 4(1):281-7. PubMed ID: 2285622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.